Health insurers step up appeal of clinics

Health insurance providers are increasingly stepping into the world of in-store clinics, becoming both the payer and the provider of care. While rival hospitals and doctor groups are keeping a close eye on the emerging trend, health insurers continue to offer more plans to entice patients into their own clinics, The Wall Street Journal reported.

Health insurers are banking on clinics bringing down costs of care by reducing hospitalizations and improving access to preventive care.

UnitedHealth Group, which owns the nation’s largest health insurance plan UnitedHealthcare, is offering a health plan around its Optum business, including its network of doctors, surgery centers and urgent care clinics.

Another provider, Blue Cross & Blue Shield of Texas, launched a plan with free primary care visits at its new clinics through a partner company in Houston and Dallas, with prices for coverage 12% to 18% below another product it offers statewide.

CVS Health’s acquisition of Aetna has led to more appealing plan choices, as well, such as no co-pays for MinuteClinic visits.

Hospitals, meanwhile, find the trend “worrisome,” as they may lose patient volume to these new choices.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.